Paper38948331
Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells.
Christensen CL and 5 others. Mol Ther Nucleic Acids, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells. Papers, record 38948331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38948331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Base editing rescues acid α-glucosidase function in infantile-onset Pompe disease patient-derived cells.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 AR079223 | NIAMS NIH HHS | United States | R01AR079223 | PubMed |
Source NIH RePORTER
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34079130 | Base editing of haematopoietic stem cells rescues sickle cell disease in mice. | Nature | 2021 | https://conductscience.org/library/papers/34079130 | PubMed |
| 2 | 32480002 | Next-Generation Sequencing in High-Sensitive Detection of Mutations in Tumors: Challenges, Advances, and Applications. | J Mol Diagn | 2020 | https://conductscience.org/library/papers/32480002 | PubMed |
| 3 | 31392190 | Molecular genetics of Pompe disease: a comprehensive overview. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31392190 | PubMed |
| 4 | 33959386 | Muscle-Specific Promoters for Gene Therapy. | Acta Naturae | 2021 | https://conductscience.org/library/papers/33959386 | PubMed |
| 5 | 35119294 | Inference of CRISPR Edits from Sanger Trace Data. | CRISPR J | 2022 | https://conductscience.org/library/papers/35119294 | PubMed |
| 6 | 34737297 | Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates. | Nat Commun | 2021 | https://conductscience.org/library/papers/34737297 | PubMed |
| 7 | 26098369 | Engineered CRISPR-Cas9 nucleases with altered PAM specificities. | Nature | 2015 | https://conductscience.org/library/papers/26098369 | PubMed |
| 8 | 22930834 | NIH Image to ImageJ: 25 years of image analysis. | Nat Methods | 2012 | https://conductscience.org/library/papers/22930834 | PubMed |
| 9 | 33013846 | A Race Against Time-Changing the Natural History of CRIM Negative Infantile Pompe Disease. | Front Immunol | 2020 | https://conductscience.org/library/papers/33013846 | PubMed |
| 10 | 15585405 | Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. | Mol Ther | 2005 | https://conductscience.org/library/papers/15585405 | PubMed |
| 11 | 34020684 | Genotype-phenotype correlation of 17 cases of Pompe disease in Spanish patients and identification of 4 novel GAA variants. | Orphanet J Rare Dis | 2021 | https://conductscience.org/library/papers/34020684 | PubMed |
| 12 | 19775921 | Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. | Mol Genet Metab | 2010 | https://conductscience.org/library/papers/19775921 | PubMed |
| 13 | 24463181 | Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. | Bioinformatics | 2014 | https://conductscience.org/library/papers/24463181 | PubMed |
| 14 | 23873081 | DNA targeting specificity of RNA-guided Cas9 nucleases. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/23873081 | PubMed |
| 15 | 34850579 | Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. | EMBO Mol Med | 2022 | https://conductscience.org/library/papers/34850579 | PubMed |
| 16 | 36624150 | Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase. | Nat Biotechnol | 2023 | https://conductscience.org/library/papers/36624150 | PubMed |
| 17 | 28814660 | Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. | JCI Insight | 2017 | https://conductscience.org/library/papers/28814660 | PubMed |
| 18 | 29813047 | Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. | Nat Biotechnol | 2018 | https://conductscience.org/library/papers/29813047 | PubMed |
| 19 | 24715333 | Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. | J Inherit Metab Dis | 2015 | https://conductscience.org/library/papers/24715333 | PubMed |
| 20 | 33116134 | Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants. | Nat Commun | 2020 | https://conductscience.org/library/papers/33116134 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941997 | The Genetic Landscape of Pompe Disease in the Middle East, North Africa, and Turkey (MENAT Region): A Systematic Review of GAA Variants and Genotype-Phenotype Correlation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941997 | PubMed |
| 41783848 | Comprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions. | Front Neurol | 2026 | https://conductscience.org/library/papers/41783848 | PubMed |
| 41345283 | Precision rewriting of muscle genetics: therapeutic horizons of base and prime editing in skeletal muscle disorders. | Gene Ther | 2026 | https://conductscience.org/library/papers/41345283 | PubMed |
| 39134822 | Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy. | Mol Diagn Ther | 2024 | https://conductscience.org/library/papers/39134822 | PubMed |
| 39100736 | Precision medicine in action for Pompe disease. | Mol Ther Nucleic Acids | 2024 | https://conductscience.org/library/papers/39100736 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GAA | 2548 | PubTator's text mining | https://conductscience.org/library/genes/2548 | NCBI Gene |
| LAMP2 | 3920 | PubTator's text mining | https://conductscience.org/library/genes/3920 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38948331
GET https://conductscience.org/api/papers/v1/38948331/references?page=2